Liquid Biopsy

Researchers at Massachusetts General Hospital have developed a new blood test to detect epidermal growth factor receptor mutations in patients with glioma — one of the most common brain cancers in adults.

Researchers at Johns Hopkins Sidney Kimmel Cancer Center have developed an automated liquid biopsy test that can detect cancer DNA in the blood of patients with metastatic breast cancer within 5 hours.

A noninvasive liquid biopsy test diagnosed the presence and severity of nonalcoholic steatohepatitis and liver fibrosis more reliably than liver biopsy, according to research published in Gut.

Within the past decade, data have emerged indicating an effective role of circulating tumor DNA in identifying lung cancer at an early stage and in matching patients with appropriate treatments.

CHICAGO — Including liquid biopsy in the initial diagnostic workup of patients with stage IV nonsquamous non-small cell lung cancer resulted in a quicker initiation of first-line therapy and a higher detection rate of actionable mutations.

CHICAGO — For patients with advanced non-small cell lung cancer who showed an inadequate response to front-line immunotherapy checkpoint inhibitors and chemotherapy, the addition of CAN-2409 was well-tolerated.

Liquid biopsy — once just a promising technology — is now an important tool for selecting treatment for certain patients with breast cancer, according to Melissa McShane, MD.

As oncologists currently lack a cure for multiple myeloma, most patients will relapse at some point. The ability to predict when this will occur, however, may lead to more personalized therapy.

In this Healio video exclusive, Charles J. Meakin, MD, MHA, chief medical officer of Care Oncology, discusses risk factors for colorectal cancer, the importance of early detection and the use of liquid biopsies as screening tools.

Charu Aggarwal, MD, MPH, spoke with Healio about a presentation she gave at this year’s Chemotherapy Foundation Symposium.